The global endovascular robotics market was valued at USD 0.21 billion in 2025. It is estimated at USD 0.26 billion in 2026 and is projected to reach USD 2.23 billion by 2036, growing at a CAGR of 24.0% over the 2026-2036 forecast period. The report reviews clinical evidence, procedure volumes and epidemiology, robotics and navigation technology, regulation and reimbursement, occupational safety, the value chain, and competition.
Endovascular robots advance and steer catheters, guidewires, balloons, stents, and similar devices through the vascular system and heart while the physician sits at a protected console, out of the path of X-ray radiation. The study covers electromechanical drives for standard catheters and guidewires, magnetic systems that steer magnet-tipped catheters with external fields, steerable robotic catheters, and newer navigation tools that use AI or work autonomously, along with single-use robots, disposable cassettes, software, and services. Clinical uses span peripheral, coronary, and neurovascular interventions, cardiac electrophysiology, structural heart procedures, and interventional oncology such as embolization. General surgical robots, robotic bronchoscopy, and separately sold imaging systems are excluded.
The market has entered a second phase of development after earlier platforms struggled, with Siemens Healthineers ending sales of the Corindus CorPath GRX for vascular procedures in 2023 and Hansen Medical's Magellan system never reaching wide use before Auris Health acquired the company in 2016. A new model arrived on 8 September 2025, when Microbot Medical's LIBERTY Endovascular Robotic System received U.S. FDA clearance as the first remotely operated, single-use robot for peripheral endovascular work. Its pivotal study reported 100% navigation success to target, no device-related adverse events, and a 92% relative cut in physician radiation exposure. The procedure base is large: Microbot Medical puts annual U.S. peripheral endovascular procedures at about 2.5 million, and according to the World Stroke Organization, roughly 12 million people suffer a stroke each year.
Adoption is held back by the sector's history of commercial setbacks, which has made hospitals cautious and left the installed base small compared with annual procedure counts. Traditional systems need capital outlay, service contracts, and disposable cassettes, while hospitals receive no extra payment for robotic procedures, and since the main proven benefit goes to staff rather than patients, purchases are hard to justify. Many robots can handle only certain guidewires and catheters, operators lose tactile feedback at the console, and each new indication, especially neurovascular, needs more clinical evidence; in Europe, Medical Device Regulation transition periods run to 2027 and 2028. Further challenges include proving patient outcome benefits beyond lower radiation, fitting robots into busy cath lab workflows, ensuring reliable networks for remote procedures, and competing with cheaper protection options such as suspended shielding and lower-dose imaging.
Remote and telerobotic stroke intervention is the most significant opportunity, since thrombectomy is time-critical and specialists are concentrated in major centers; the first remote coronary stenting, in 2018, was done with the physician about 20 miles from the patient, and Sentante, XCath, and Nanoflex Robotics are among the developers building systems for remote stroke care. Outpatient peripheral work in ambulatory surgery centers and office-based labs, where capital budgets are tight, suits single-use robots, and robotic electrophysiology and structural heart procedures offer further room to grow; according to the Global Burden of Disease study, atrial fibrillation affected an estimated 59 million people worldwide. Key trends include the shift to single-use systems and per-procedure revenue, AI-assisted and autonomous guidance, remote telerobotic procedures, and progress in magnetic steering and microrobots.
By technology, the study covers electromechanical catheter & guidewire robots, magnetic navigation systems, robotic steerable catheters, and AI-guided navigation. Magnetic navigation systems are expected to hold the largest share in 2026, reflecting their established installed base in cardiac electrophysiology, Stereotaxis' more than two decades of clinical use since its first FDA clearance in 2003, and their ability to steer soft catheters precisely within the heart with a lower risk of perforation. Electromechanical catheter & guidewire robots are expected to grow at the highest CAGR, driven by single-use systems such as LIBERTY, new platforms for coronary, peripheral, and neurovascular procedures, and designs that work with standard devices.
The product analysis separates robotic systems, single-use robots & disposables, and software & services. Robotic systems are expected to account for the largest share in 2026, given the capital value of installed magnetic navigation and robotic platforms, the high price of each console, and the long service life of these systems in hospital cath labs. Single-use robots & disposables are expected to grow at the highest CAGR, as per-procedure models remove the capital hurdle, link revenue directly to procedure volume, and open the door to outpatient centers that cannot fund large equipment purchases. Software & services gain importance as AI navigation, imaging integration, and remote operation are added to platforms.
By application, the report covers peripheral vascular, coronary, neurovascular (stroke thrombectomy and aneurysm & other neurovascular procedures), cardiac electrophysiology, structural heart, and interventional oncology. Cardiac electrophysiology is expected to hold the largest share in 2026, as magnetic navigation is widely used in ablation procedures, rising atrial fibrillation volumes require precise and repeatable catheter control, and this application has the longest clinical track record. Peripheral vascular is expected to grow at the highest CAGR, supported by about 2.5 million annual U.S. peripheral procedures, the launch of FDA-cleared single-use robots, and the movement of these procedures to outpatient sites. Neurovascular procedures, especially stroke thrombectomy, are a key long-term focus because of the potential of remote intervention.
By end user, the study covers hospitals, ambulatory surgery centers & office-based labs, and specialty cardiac & neurovascular centers. Hospitals are expected to account for the largest share in 2026, as complex endovascular procedures, imaging equipment, and capital budgets are concentrated in hospital cath labs, and most installed robotic and magnetic navigation systems sit there. Ambulatory surgery centers & office-based labs are expected to grow at the highest CAGR, as peripheral interventions continue to move to outpatient settings and single-use robots require no capital investment.
North America is expected to be the largest regional market in 2026, supported by high procedure volumes, early use of medical robotics, and the presence of leading developers. The U.S. is the launch market for LIBERTY, which started with a limited rollout in November 2025, ahead of a full launch planned for April 2026, while U.S.-based Stereotaxis supplies magnetic navigation for electrophysiology and XCath is working on neurovascular robotics. Europe also holds a significant share and hosts several developers, including France's Robocath, whose R-One coronary platform gained CE marking in 2019, Switzerland's Nanoflex Robotics, and Lithuania's Sentante. The 2013/59/Euratom directive, which lowered the annual eye lens dose limit for workers to 20 millisieverts in line with the International Commission on Radiological Protection, has raised attention to staff protection.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by large and rising procedure volumes, aging populations, and strong domestic robotics industries. China performs well over one million percutaneous coronary interventions a year and has several local vascular robot developers, and Robocath has partnered with MicroPort to bring its technology to China. Japan has one of the world's oldest populations, while India, South Korea, and Australia are adding cath lab capacity. In Latin America, Brazil, Mexico, Argentina, and Colombia are expanding cardiovascular and stroke programs, and the need to reach remote patients makes telerobotics relevant. In the Middle East & Africa, Gulf states are building advanced cardiac and neurovascular centers, Israel is a base for robotics research, and the International Diabetes Federation estimates that the Middle East and North Africa has about 73 million adults with diabetes.
The market is still young, with participants ranging from magnetic navigation suppliers to makers of electromechanical and single-use catheter robots, neurovascular and remote intervention startups, large medtech groups with robotics portfolios, and Chinese robotics developers. Companies compete on device compatibility, range of procedures, radiation reduction, workflow fit, cost model, clinical evidence, regulatory clearances, and remote capability. Leading players are seeking clearances for new indications, moving to single-use and per-procedure pricing, adding AI-assisted navigation, partnering with catheter makers and regional distributors, and building telerobotic capability, while large medtech firms reassess the category after earlier exits.
Key companies profiled in the report include Stereotaxis, Inc. (U.S.), Microbot Medical Inc. (U.S./Israel), Robocath (France), MicroPort Scientific Corporation (China), Siemens Healthineers AG (Corindus) (Germany), Johnson & Johnson MedTech (U.S.), Nanoflex Robotics AG (Switzerland), XCath, Inc. (U.S.), Sentante (Lithuania), and Capstan Medical (U.S.).
Endovascular robots advance and steer catheters, guidewires, balloons, stents, and similar devices through the vascular system and heart while the physician sits at a protected console, out of the path of X-ray radiation. The study covers electromechanical drives for standard catheters and guidewires, magnetic systems that steer magnet-tipped catheters with external fields, steerable robotic catheters, and newer navigation tools that use AI or work autonomously, along with single-use robots, disposable cassettes, software, and services. Clinical uses span peripheral, coronary, and neurovascular interventions, cardiac electrophysiology, structural heart procedures, and interventional oncology such as embolization. General surgical robots, robotic bronchoscopy, and separately sold imaging systems are excluded.
The market has entered a second phase of development after earlier platforms struggled, with Siemens Healthineers ending sales of the Corindus CorPath GRX for vascular procedures in 2023 and Hansen Medical's Magellan system never reaching wide use before Auris Health acquired the company in 2016. A new model arrived on 8 September 2025, when Microbot Medical's LIBERTY Endovascular Robotic System received U.S. FDA clearance as the first remotely operated, single-use robot for peripheral endovascular work. Its pivotal study reported 100% navigation success to target, no device-related adverse events, and a 92% relative cut in physician radiation exposure. The procedure base is large: Microbot Medical puts annual U.S. peripheral endovascular procedures at about 2.5 million, and according to the World Stroke Organization, roughly 12 million people suffer a stroke each year.
Market Dynamics
Occupational hazards are the leading driver, as interventional cardiologists, radiologists, and neurointerventionalists spend long hours beside the X-ray source in heavy lead aprons, and surveys have linked this work to spine, neck, and joint problems. Radiation concerns were sharpened by a case series reported in 2013 that described brain tumors in 31 interventional physicians, with 85% located on the left side of the head, which usually faces the X-ray tube. Robots let operators work from a protected console without aprons, which matters as cath labs focus on retaining staff. Procedure growth is a second driver. Over 200 million people globally live with peripheral artery disease, mechanical thrombectomy is now standard for large-vessel stroke, and the World Health Organization expects people aged 60 or above to make up one-sixth of the world population by 2030. New business models add a third driver, as single-use robots that work with physicians' preferred tools and fit existing workflows remove the need for large capital budgets.Adoption is held back by the sector's history of commercial setbacks, which has made hospitals cautious and left the installed base small compared with annual procedure counts. Traditional systems need capital outlay, service contracts, and disposable cassettes, while hospitals receive no extra payment for robotic procedures, and since the main proven benefit goes to staff rather than patients, purchases are hard to justify. Many robots can handle only certain guidewires and catheters, operators lose tactile feedback at the console, and each new indication, especially neurovascular, needs more clinical evidence; in Europe, Medical Device Regulation transition periods run to 2027 and 2028. Further challenges include proving patient outcome benefits beyond lower radiation, fitting robots into busy cath lab workflows, ensuring reliable networks for remote procedures, and competing with cheaper protection options such as suspended shielding and lower-dose imaging.
Remote and telerobotic stroke intervention is the most significant opportunity, since thrombectomy is time-critical and specialists are concentrated in major centers; the first remote coronary stenting, in 2018, was done with the physician about 20 miles from the patient, and Sentante, XCath, and Nanoflex Robotics are among the developers building systems for remote stroke care. Outpatient peripheral work in ambulatory surgery centers and office-based labs, where capital budgets are tight, suits single-use robots, and robotic electrophysiology and structural heart procedures offer further room to grow; according to the Global Burden of Disease study, atrial fibrillation affected an estimated 59 million people worldwide. Key trends include the shift to single-use systems and per-procedure revenue, AI-assisted and autonomous guidance, remote telerobotic procedures, and progress in magnetic steering and microrobots.
Segment Analysis
The report analyzes the market by technology, product, application, end user, and geography, helping stakeholders identify where adoption and revenue are likely to grow.By technology, the study covers electromechanical catheter & guidewire robots, magnetic navigation systems, robotic steerable catheters, and AI-guided navigation. Magnetic navigation systems are expected to hold the largest share in 2026, reflecting their established installed base in cardiac electrophysiology, Stereotaxis' more than two decades of clinical use since its first FDA clearance in 2003, and their ability to steer soft catheters precisely within the heart with a lower risk of perforation. Electromechanical catheter & guidewire robots are expected to grow at the highest CAGR, driven by single-use systems such as LIBERTY, new platforms for coronary, peripheral, and neurovascular procedures, and designs that work with standard devices.
The product analysis separates robotic systems, single-use robots & disposables, and software & services. Robotic systems are expected to account for the largest share in 2026, given the capital value of installed magnetic navigation and robotic platforms, the high price of each console, and the long service life of these systems in hospital cath labs. Single-use robots & disposables are expected to grow at the highest CAGR, as per-procedure models remove the capital hurdle, link revenue directly to procedure volume, and open the door to outpatient centers that cannot fund large equipment purchases. Software & services gain importance as AI navigation, imaging integration, and remote operation are added to platforms.
By application, the report covers peripheral vascular, coronary, neurovascular (stroke thrombectomy and aneurysm & other neurovascular procedures), cardiac electrophysiology, structural heart, and interventional oncology. Cardiac electrophysiology is expected to hold the largest share in 2026, as magnetic navigation is widely used in ablation procedures, rising atrial fibrillation volumes require precise and repeatable catheter control, and this application has the longest clinical track record. Peripheral vascular is expected to grow at the highest CAGR, supported by about 2.5 million annual U.S. peripheral procedures, the launch of FDA-cleared single-use robots, and the movement of these procedures to outpatient sites. Neurovascular procedures, especially stroke thrombectomy, are a key long-term focus because of the potential of remote intervention.
By end user, the study covers hospitals, ambulatory surgery centers & office-based labs, and specialty cardiac & neurovascular centers. Hospitals are expected to account for the largest share in 2026, as complex endovascular procedures, imaging equipment, and capital budgets are concentrated in hospital cath labs, and most installed robotic and magnetic navigation systems sit there. Ambulatory surgery centers & office-based labs are expected to grow at the highest CAGR, as peripheral interventions continue to move to outpatient settings and single-use robots require no capital investment.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 21 countries and five rest-of-region groups. The regional analysis considers procedure volumes, disease burden, regulatory pathways, reimbursement, catheterization laboratory capacity, and the presence of robotics developers.North America is expected to be the largest regional market in 2026, supported by high procedure volumes, early use of medical robotics, and the presence of leading developers. The U.S. is the launch market for LIBERTY, which started with a limited rollout in November 2025, ahead of a full launch planned for April 2026, while U.S.-based Stereotaxis supplies magnetic navigation for electrophysiology and XCath is working on neurovascular robotics. Europe also holds a significant share and hosts several developers, including France's Robocath, whose R-One coronary platform gained CE marking in 2019, Switzerland's Nanoflex Robotics, and Lithuania's Sentante. The 2013/59/Euratom directive, which lowered the annual eye lens dose limit for workers to 20 millisieverts in line with the International Commission on Radiological Protection, has raised attention to staff protection.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by large and rising procedure volumes, aging populations, and strong domestic robotics industries. China performs well over one million percutaneous coronary interventions a year and has several local vascular robot developers, and Robocath has partnered with MicroPort to bring its technology to China. Japan has one of the world's oldest populations, while India, South Korea, and Australia are adding cath lab capacity. In Latin America, Brazil, Mexico, Argentina, and Colombia are expanding cardiovascular and stroke programs, and the need to reach remote patients makes telerobotics relevant. In the Middle East & Africa, Gulf states are building advanced cardiac and neurovascular centers, Israel is a base for robotics research, and the International Diabetes Federation estimates that the Middle East and North Africa has about 73 million adults with diabetes.
Competitive Landscape
The report reviews key growth strategies, competitive benchmarking, the competitive dashboard with industry leaders, market differentiators, vanguards, and emerging companies, and market share/rank analysis by key player for 2025, together with company profiles covering business overview, financial performance, product portfolio, strategic developments, and SWOT analysis.The market is still young, with participants ranging from magnetic navigation suppliers to makers of electromechanical and single-use catheter robots, neurovascular and remote intervention startups, large medtech groups with robotics portfolios, and Chinese robotics developers. Companies compete on device compatibility, range of procedures, radiation reduction, workflow fit, cost model, clinical evidence, regulatory clearances, and remote capability. Leading players are seeking clearances for new indications, moving to single-use and per-procedure pricing, adding AI-assisted navigation, partnering with catheter makers and regional distributors, and building telerobotic capability, while large medtech firms reassess the category after earlier exits.
Key companies profiled in the report include Stereotaxis, Inc. (U.S.), Microbot Medical Inc. (U.S./Israel), Robocath (France), MicroPort Scientific Corporation (China), Siemens Healthineers AG (Corindus) (Germany), Johnson & Johnson MedTech (U.S.), Nanoflex Robotics AG (Switzerland), XCath, Inc. (U.S.), Sentante (Lithuania), and Capstan Medical (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global endovascular robotics market through 2036.
- Explains how occupational radiation and orthopedic risks, rising procedure volumes, and single-use robots are shaping adoption.
- Assesses the impact of past commercial setbacks, missing reimbursement, device compatibility limits, and regulatory hurdles.
- Identifies high-growth opportunities across technology, product, application, end user, and region.
- Tracks emerging technologies such as AI-guided navigation, telerobotic stroke intervention, magnetic navigation, and microrobotics.
- Benchmarks leading companies on technology, clinical evidence, regulatory status, business model, and market position.
- Supports product development, regulatory planning, commercialization, partnership, and investment decisions for device makers, hospitals, and investors.
Key Questions Answered
- How large is the global endovascular robotics market today, and how will it grow through 2036?
- Why did earlier platforms such as CorPath GRX and Magellan fail to achieve broad adoption, and what has changed since?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will single-use, per-procedure robots such as LIBERTY change the economics of robotic intervention?
- Which technology, product, application, and end user segments will grow the fastest?
- How close is telerobotic stroke thrombectomy to routine clinical use, and what network and regulatory hurdles remain?
- What clinical evidence exists on technical success, safety, and operator radiation reduction?
- Which regions and countries offer the most attractive opportunities for robotics developers?
- Who are the leading companies in the market, and what strategies are they using to compete?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Endovascular Robotics Market, by Technology
6. Endovascular Robotics Market, by Product
7. Endovascular Robotics Market, by Application
8. Endovascular Robotics Market, by End User
9. Endovascular Robotics Market, by Geography
10. Competitive Landscape
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Stereotaxis, Inc.
- Microbot Medical Inc.
- Robocath
- MicroPort Scientific Corporation
- Siemens Healthineers AG
- Johnson & Johnson MedTech
- Nanoflex Robotics AG
- XCath, Inc.
- Sentante
- Capstan Medical
